AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2025

Revenue declinedEmphasis of matterResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹18.50

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-0.1% vs market

Pharmaceuticals peers, median of 147sector-0.1%+0.1% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+0.1-0.1-0.1+0.1

Next day

+4.3-0.2+4.5-0.3+4.6

+8.9+0.3+8.6-0.3+9.2

+5.4+0.9+4.6+0.0+5.4

+5.4+0.8+4.6+0.0+5.4

+5.1+2.2+3.0+0.6+4.5

+3.2+3.4-0.1+1.4+1.8

15d

+1.7-0.8+2.5-3.0+4.8

+26.8+2.9+23.9+0.2+26.6

+13.0+0.8+12.1-0.5+13.5

+38.6+0.0+38.6-3.4+42.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Beryl Drugs Ltd reported total revenue from operations of ₹2,255.48 lakhs for FY25, down from ₹2,712.48 lakhs in FY24 — a decline of about 16.8%. Net profit fell to ₹57.89 lakhs from ₹76.86 lakhs, a drop of roughly 24.7%, with basic EPS at ₹1.14 versus ₹1.51. The revenue dip was largely due to a temporary halt in production at the FFS section from January 2025 to upgrade to revised Schedule M / WHO-GMP norms (certification received on 27 March 2025). Despite weaker top line, operating cash flow improved sharply to ₹263.67 lakhs from ₹82.02 lakhs. Total equity rose to ₹950.38 lakhs and overall borrowings declined. The auditor gave an unmodified opinion but flagged four emphasis-of-matter items: a Kotak Mahindra Bank loan of ₹175 lakhs (taken Nov 2021) where no charge was registered (now fully repaid), write-back of old statutory dues (~₹5.28 lakhs), the production shutdown, and ₹23.75 lakhs of trade receivables written off as irrecoverable.

Likely market impact

The decline reflects a temporary production disruption rather than structural weakness, and the WHO-GMP certification positions the company for potential recovery. However, the emphasis-of-matter notes — especially the unregistered loan charge and recurring receivable write-offs — flag governance concerns shareholders should watch, even though no audit qualifications were raised.